Research graph
References from In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics
2011 · External reference
Malignant gliomas in adults
10.1056/nejmra0708126 · 2008 · External reference
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
10.1038/nrc2818 · 2010 · External reference
Therapeutic options for recurrent malignant glioma
10.1016/j.radonc.2010.11.006 · 2011 · External reference
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
10.1016/s1470-2045(09)70025-7 · 2009 · External reference
Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches
10.4161/cbt.2.4.507 · 2003 · External reference
Molecular alterations of KIT oncogene in gliomas
2007 · External reference
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas
10.1038/sj.bjc.6605225 · 2009 · External reference
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
10.1038/nature07385 · 2008 · External reference
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma
10.1016/j.ccr.2011.11.005 · 2011 · External reference
Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity
10.1158/0008-5472.can-11-4069 · 2012 · External reference
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
10.1073/pnas.1114033109 · 2012 · External reference
Angiogenesis in malignant glioma—a target for antitumor therapy?
10.1016/j.critrevonc.2006.01.004 · 2006 · External reference
Novel anti-angiogenic therapies for malignant gliomas
10.1016/s1474-4422(08)70260-6 · 2008 · External reference
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
10.1056/nejm200104053441402 · 2001 · External reference
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
10.1056/nejmoa020461 · 2002 · External reference
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
10.1056/nejmoa065044 · 2007 · External reference
Sorafenib in advanced hepatocellular carcinoma
10.1056/nejmoa0708857 · 2008 · External reference
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours
10.1016/j.ejca.2009.05.008 · 2009 · External reference
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
10.1158/1078-0432.ccr-06-0773 · 2006 · External reference
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
10.1200/jco.2008.16.3055 · 2009 · External reference
Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis
10.6004/jnccn.2011.0037 · 2011 · External reference
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
10.1073/pnas.1014480108 · 2011 · External reference
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
10.1093/neuonc/nop068 · 2010 · External reference
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies
10.2165/11318860-000000000-00000 · 2009 · External reference
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models
10.1002/path.2836 · 2011 · External reference
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib
10.1093/neuonc/noq017 · 2010 · External reference
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
10.1215/15228517-2007-024 · 2007 · External reference
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide
10.1158/1078-0432.ccr-07-4544 · 2008 · External reference
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
2003 · External reference
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models
2003 · External reference
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
10.1007/s11060-010-0402-7 · 2010 · External reference
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
10.1158/0008-5472.can-04-4409 · 2005 · External reference
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family
10.1158/1535-7163.mct-10-0976 · 2011 · External reference
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
10.1200/jco.2009.26.3988 · 2010 · External reference
Normalization of tumor vasculature and alleviation of edema by AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor in glioblastoma patients
10.1016/j.ijrobp.2007.07.092 · 2007 · External reference
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
10.1016/j.ccr.2006.11.021 · 2007 · External reference
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
10.1200/jco.2008.19.9356 · 2009 · External reference
Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas
10.1371/journal.pone.0030769 · 2012 · External reference
Angiogenic potential of Gellan-gum-based hydrogels for application in nucleus pulposus regeneration: in vivo study
10.1089/ten.tea.2011.0632 · 2012 · External reference
Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness
10.1093/hmg/dds405 · 2013 · External reference
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
10.1038/sj.onc.1209497 · 2006 · External reference
Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells
10.1002/ijc.24030 · 2009 · External reference
In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation
10.1007/s11060-009-9975-4 · 2010 · External reference
Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity
10.1007/s00432-006-0109-5 · 2006 · External reference
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins
2010 · External reference
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines
10.1007/s10637-009-9290-0 · 2010 · External reference
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic
10.1007/s11060-011-0580-y · 2011 · External reference
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts
10.1016/j.ijrobp.2010.09.019 · 2010 · External reference
Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape
10.1158/0008-5472.can-10-2602 · 2011 · External reference
Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment
10.1093/jnci/djm187 · 2007 · External reference
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells
10.1111/j.1742-7843.2008.00371.x · 2009 · External reference
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
10.1126/science.1142946 · 2007 · External reference
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
10.1126/science.1141478 · 2007 · External reference
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
10.1038/sj.onc.1210173 · 2007 · External reference
Molecular alterations of KIT oncogene in gliomas
2007 · External reference
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas
10.1038/sj.bjc.6605225 · 2009 · External reference
KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops
10.1016/j.ygyno.2008.07.011 · 2008 · External reference
